Bemcentinib – A selective AXL inhibitor currently in Phase II
Learn MoreLATEST NEWS
BerGenBIO APPOINTS ANDERS TULLGREN as Chairman of Board
Read moreScientific Presentations
ASH 2021, Sonja Loges et al.
13th December 2021
Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results indicating Bemcentinib elicits anti-AML immune responses.
Corporate Presentation
Read more
Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.
BerGenBio’s lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Additionally, bemcentinib has been reported to exhibit potent anti-viral activity in preclinical models of infection by enveloped viruses, including Ebola and Zika. Recent data have expanded this to SARS-CoV-2 where findings suggest that bemcentinib stops the virus entering the host cells and neutralising its anti-viral defence mechanisms. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BerGenBIO APPOINTS ANDERS TULLGREN as Chairman of Board
Bergen, Norway, 6 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces today the appointment of Anders
Read moreBERGENBIO announces EXCLUSIVE in-licensE of key intellectual property rights from ut Southwestern Medical center
In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations Bergen, Norway, 16 December 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical
Read moreBERGENBIO PRESENTS UPDATED Bemcentinib AML DATA at ASH 2021 MEETING
Bergen, Norway, 13 December 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased
Read moreBERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Bergen, Norway, 16 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the
Read more
